Bajaj Healthcare Limited has informed the Exchange about General Updates
BAJAJHCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bajaj Healthcare Limited has received approval from the Central Drugs Standard Control Organisation (CDSCO) on December 31, 2025, to conduct a Clinical Trial and Bioequivalence Study of Suvorexant Tablets. This follows the earlier recommendation from the Subject Expert Committee (Neurology & Psychiatry) of CDSCO in October 2025 for conducting Phase III clinical trials. Suvorexant is used in the treatment of insomnia. The approval enables the company to proceed with the clinical trial phase of this molecule.
This is a positive regulatory milestone that allows Bajaj Healthcare to advance its Suvorexant Tablets development pipeline, potentially strengthening its future product portfolio in the neurology/psychiatry segment. No immediate revenue impact as the product is still in clinical trial stage.